

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

DATE MAILED:

Washington, D.C. 20231

重り

APPLICATION NO. **FILING DATE** FIRST NAMED INVENTOR ATTORNEY DOCKET NO. Q60688 Z **AGUR** 10/19/00 09/691,053 **EXAMINER** HM12/0226 LIN, J SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLL 2100 PENNSYLVANIA AVENUE, N.W. **ART UNIT** PAPER NUMBER WASHINGTON DC 20037-3213 1631

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

02/26/01

Office Action Summary	Application No.	Application No. Applicant(s)		
	09/691,053	AGUR, ZVIA	AGUR, ZVIA	
	Examiner	Art Unit		
	Jerry Lin	1631		
The MAILING DATE of this communication a	ppears on the cover sheet w	ith the correspondence ac	Idress	
A SHORTENED STATUTORY PERIOD FOR REATHER MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a result of the period for reply is specified above, the maximum statutory perions to reply within the set or extended period for reply will, by state. Any reply received by the Office later than three months after the material patent term adjustment. See 37 CFR 1.704(b). Status	N. 1.136 (a). In no event, however, may a reply within the statutory minimum of this iod will apply and will expire SIX (6) MO	a reply be timely filed irty (30) days will be considered time INTHS from the mailing date of this o	ely. communication.	
1) Responsive to communication(s) filed on _				
	This action is non-final.			
3) Since this application is in condition for allocation is in condition for allocation is in condition for allocation accordance with the practice under	Wance except for formal ma	atters, prosecution as to the D. 11, 453 O.G. 213.	ne merits is	
Disposition of Claims				
4) Claim(s) 1-509 is/are pending in the applica	tion.			
4a) Of the above claim(s) is/are withdr				
5) Claim(s) is/are allowed.				
6)☐ Claim(s) is/are rejected.				
7) Claim(s) is/are objected to.				
8) Claims 1-509 are subject to restriction and/o	or election requirement.			
Application Papers				
9) The specification is objected to by the Exami	ner.			
10) The drawing(s) filed on is/are objected				
11) The proposed drawing correction filed on		disapproved		
12) The oath or declaration is objected to by the B	Examiner.	uisappioveu.		
Priority under 35 U.S.C. § 119				
13) Acknowledgment is made of a claim for foreig	an priority under 35 U.S.C. s	(110/a) (d) ar (f)		
a) All b) Some * c) None of:	in priority under 33 O.S.C. §	119(a)-(d) or (f).		
1. Certified copies of the priority documen	ate have been received			
		an Baatan No		
			. .	
3. Copies of the certified copies of the pricapplication from the International But See the attached detailed Office action for a list	ureau (PCT Rule 17 2(a))		stage	
14) Acknowledgement is made of a claim for dome				
Attachment(s)				
 15) Notice of References Cited (PTO-892) 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 	10\ Nation at i	Summary (PTO-413) Paper No(nformal Patent Application (PTC	s) D-152)	

Application/Control Number: 09/691,053

Art Unit: 1631

The art unit designated for this application has changed. Applicant (s) are hereby informed that future correspondence should be direct to Art Unit 1631.

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-65, 234-331, 466-509, drawn to a method and apparatus for recommending an optimal treatment protocol, classified in class 702, subclass 19.
- II. Claims 66-167, 332-349, drawn to a method of modeling Thrombopietic lineage, classified in class 702, subclass 19.
- III. Claims 168-233, 400-433, drawn to a method of modeling Neutrophil lineage, classified in class 702, subclass 19.
- IV. Claims 350-399, drawn to a method of predicting the progression of
 Thrombopoeisis and Thrombocytopenia, classified in class 702, subclass
 19.
- V. Claims 434-465, drawn to a method of predicting the progression of Granulopoiesis, classified in class 702, subclass 19.

The inventions are distinct, each from the other because of the following reasons:

Inventions I, II, III, IV and V are related as subcombinations disclosed as usable together in a single combination. The subcombinations are distinct from each other if they are shown to be separately usable. In the instant case, invention I has separate

Application/Control Number: 09/691,053

Art Unit: 1631

utility such as recommending a treatment for only cancer. Invention II has separate utility such modeling Thrombopietic lineage for basic science research, not for treatment or drug development. Invention III has separate utility such as modeling Neutrophil lineage for basic science research, not for treatment or drug development. Invention IV has separate utility such as testing the efficacy of a drug in development for Thrombopoeisis. Invention V has separate utility such as testing the efficacy of a drug in development for Granulopoiesis. Thus, Inventions I, II, III, IV or V do not require any of the other inventions to practice the above utilities. See MPEP § 806.05(d).

Because these inventions are distinct for the reasons given above and the search required for Group I, II, III, IV, or V is not required for any of the other Groups, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jerry Lin whose telephone number is (703) 306-5439. The examiner can normally be reached on 7:30am-4:30pm M-F.

Application/Control Number: 09/691,053

Art Unit: 1631

Page 4

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Micheal Woodward can be reached on (703) 308-4028. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-3014 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to Patent Analyst, Tina Plunkett, whose telephone number is (703) 305-3524 or to the Technical Center receptionist whose telephone number is (703) 308-0196.

Jerry Lin

February 22, 2001

ARDIN H. MARSCHEL PRIMARY EXAMINER